Business
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Recently announced AWARE-1 data further support the potential of pelareorep to induce a durable anti-tumor immune memory effect and improve outcomes in breast cancer\n \n \n Initiated dosing in phase 2 IRENE study evaluating pelareorep-anti-PD-1 combination treatment in triple-negative breast cancer\n \n \n Roche, Oncolytics, and AIO initiated GOBLET phase 1/2 study to evaluate pelareorep's potential to increase the proportion of gastrointestinal cancer patients responding to checkpoint inhibitors\n \n \n Management hosting a conference call and webcast today at 5:00 pm ET\n \n \n Canada NewsWire\n \n \n SAN DIEGO, and CALGARY, AB, Nov. 11, 2020\n \n \n \n \n \n SAN DIEGO\n \n , and\n \n CALGARY, AB\n \n ,\n \n Nov. 11, 2020\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended\n \n September 30, 2020\n \n . All dollar amounts are expressed in Canadian currency unless otherwise noted.\n \n \n \n \n \n \"We continue to execute on our clinical and corporate milestones to expand the understanding and clinical benefit of pelareorep,\" said Dr.\n \n Matt Coffey\n \n , President and Chief Executive Officer of Oncolytics Biotech Inc. \"Clinical AWARE-1 data presented at SITC 2020 demonstrated the ability of pelareorep to reverse immunosuppressive tumor microenvironments and generate the anti-tumor T cell clones needed for a durable anti-cancer immune memory effect. These findings reinforce the survival benefit observed in a prior phase 2 study and bode well for a successful outcome of our BRACELET-1 trial, w...